Novartis Meningococcal B Vaccine (OMV-based)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Novartis Meningococcal B Vaccine (OMV-based), covering 2015-02-20 to 2015-02-20. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years [Phase 3]